Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma (Q44661979)

5 December 2017

Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma (English)

1 reference

5 December 2017

1 reference

1 reference

adult oligodendroglioma

1 reference

1

1 reference

5 December 2017

8

1 reference

5 December 2017

10

Wolfgang Wick

1 reference

5 December 2017

14

Andreas von Deimling

1 reference

5 December 2017

4

David Capper

1 reference

PubMed ID

25143301

5 December 2017

Christel Herold-Mende

series ordinal

9

object named as

Christel Herold-Mende

1 reference

5 December 2017

5

Jens Schittenhelm

1 reference

5 December 2017

7

David T W Jones

1 reference

5 December 2017

2

David Reuss

1 reference

5 December 2017

3

Christian Koelsche

1 reference

5 December 2017

13

Werner Paulus

1 reference

5 December 2017

6

Stephanie Heim

1 reference

5 December 2017

Wolf Mueller

11

1 reference

PubMed ID

25143301

5 December 2017

Christian Hartmann

series ordinal

12

1 reference

5 December 2017

21 August 2014

1 reference

5 December 2017

Acta Neuropathologica

1 reference

5 December 2017

128

1 reference

5 December 2017

4

1 reference

5 December 2017

551-559

1 reference

https://scigraph.springernature.com/pub.10.1007/s00401-014-1326-7

5 December 2017

0 references

cites work

Analysis of the IDH1 codon 132 mutation in brain tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1326-7

Advantage of treating anaplastic gliomas with aggressive protocol combining chemotherapy and radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1326-7

Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1326-7

Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1326-7

Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1326-7

Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1326-7

Monoclonal antibody specific for IDH1 R132H mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1326-7

Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1326-7

Oligodendrogliomas. Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1326-7

Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1326-7

Clinical utility of fluorescence in situ hybridization (FISH) in morphologically ambiguous gliomas with hybrid oligodendroglial/astrocytic features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1326-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1326-7

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1326-7

Alterations in p53, p21, and MIB-1 labeling index in primary human astrocytomas following radiation therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1326-7

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1326-7

Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1326-7

Chromogenic in situ hybridization is a reliable alternative to fluorescence in situ hybridization for diagnostic testing of 1p and 19q loss in paraffin-embedded gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1326-7

Clonal analysis in recurrent astrocytic, oligoastrocytic and oligodendroglial tumors implicates IDH1- mutation as common tumor initiating event

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1326-7

Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1326-7

Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1326-7

Molecular and morphologic correlates of the alternative lengthening of telomeres phenotype in high-grade astrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1326-7

Oligodendroglial neoplasms: current concepts, misconceptions, and folklore

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1326-7

Glioma IDH1 mutation patterns off the beaten track.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1326-7

Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1326-7

CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1326-7

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1326-7

Mixed oligoastrocytomas: a survival and prognostic factor analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1326-7

Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1326-7

Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1326-7

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1326-7

ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1326-7

Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1326-7

Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1326-7

Oligodendroglial tumors frequently demonstrate hypermethylation of the CDKN2A (MTS1, p16INK4a), p14ARF, and CDKN2B (MTS2, p15INK4b) tumor suppressor genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1326-7

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1326-7

10.1007/S00401-014-1326-7

21 January 2018

Identifiers

DOI

1 reference

5 December 2017

1 reference

PubMed ID

25143301